Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10502 + apatinib
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10502 + apatinib is an investigational combination therapy for advanced solid tumors. HS-10502 is an orally bioavailable, selective poly(ADP-ribose) polymerase 1 (PARP1) inhibitor developed by Jiangsu Hansoh Pharmaceutical. It acts by inhibiting PARP1, a key enzyme involved in DNA repair, thereby promoting cancer cell death when combined with other antitumor agents[1][8]. Apatinib (also known as rivoceranib or YN968D1; brand name Aitan) is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis and tumor growth[5][7]. The combination is being evaluated in phase I clinical trials for safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors including recurrent ovarian cancer, HER2-negative advanced breast cancer, triple-negative breast cancer (TNBC), advanced prostate cancer, and advanced gastric cancer[6].
- Other names
- rivoceranibapatinib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on HS-10502 + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10502 + apatinib.